{"links":{"feed":"https://www.erudio.com/reports/trust-iii-nct06564324/feed.json","html":"https://www.erudio.com/reports/trust-iii-nct06564324","json":"https://www.erudio.com/reports/trust-iii-nct06564324.json","markdown":"https://www.erudio.com/reports/trust-iii-nct06564324.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"trust-iii-nct06564324"}},"request":"https://www.erudio.com/contact?report=trust-iii-nct06564324"},"offer":{"cited_clinicians":2,"cited_commentary_sources":3,"verified_hcp_statements":12,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":3},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=trust-iii-nct06564324","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=trust-iii-nct06564324","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/trust-iii-nct06564324","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 12 verified statements · 9 from 2 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T07:02:45.780426Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: PFS (Assessed by BIRC)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":1,"title":"Role of MAIC and real-world analyses alongside direct comparisons"}],"counts":{"cited_clinicians":2,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":1},"cited_physicians":2,"cited_sources":4,"claims_by_expression_type":{"comparison":3,"interpretation":2,"opinion":3,"primary_context":2,"restatement":2},"claims_by_kind":{"protocol_statement":2,"source_observation":10},"clinician_statements":9,"evidence_units":8,"findings":3,"people_cited":3,"people_identity_verified":3,"people_total":3,"screened_sources":10,"verified_claims":12},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":1,"views":2},"limitations":3,"links":{"context":2,"support":5},"ma_question":true,"named_voices":2,"passages":4,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Taletrectinib efficacy: what clinicians highlight in indirect TKI-naïve comparisons","title_holders":{"cited_claim_ids":["claim-7a3c605dbc0b2a6dc17e","claim-106a19224acd92253b38","claim-dc792fa425545030f2b9"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 2 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":2,"views":0},"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"CNS: what most speakers highlight; a clinician sees similar MAIC grade ≥3 TRAE rates","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-90821b319a74810cac8d"],"clause":"a clinician sees similar MAIC grade ≥3 TRAE rates","holders":1},"cited_claim_ids":["claim-7a3c605dbc0b2a6dc17e","claim-0204ee7d3930bf2d0019"],"clinicians":false,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"4 statements from 3 speakers in 3 sources, 1 of them a podcast or video","holder_line":"2 of the 3 named speakers in this finding hold this view; 1 of the 3 holds its caveat, “a clinician sees similar MAIC grade ≥3 TRAE rates”"},{"cited_clinicians":1,"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"MAIC: a clinician values it pending phase 3 data, but favors direct trials","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-b68e19f3ad36c4c6f2b4"],"clause":"favor direct trials","holders":1},"cited_claim_ids":["claim-434895156003d521639e","claim-b68e19f3ad36c4c6f2b4"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source, a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “favor direct trials”"}],"open_question":{"basis":"From findings F1 (5 statements from 2 speakers in 2 sources) and F3 (4 statements from 1 speaker in 1 source)","cited_claim_ids":["claim-ed553f097d96b4a72852","claim-7a3c605dbc0b2a6dc17e","claim-997e44fdfa270c8e790f","claim-106a19224acd92253b38","claim-dc792fa425545030f2b9","claim-3157445984de452ee483","claim-434895156003d521639e","claim-b68e19f3ad36c4c6f2b4"],"finding_ids":["F1","F3"],"question":"What do clinicians still need to see from TRUST-III on progression-free and overall survival to guide taletrectinib versus crizotinib use in TKI-naïve, locally advanced or metastatic ROS1-positive NSCLC?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"What can the separate MAIC and cross-study comparisons say about taletrectinib versus crizotinib?"},{"id":"section-2","level":2,"title":"Two X accounts emphasize CNS activity and low neurotoxicity; one speaker gives a narrower safety comparison"},{"id":"section-3","level":2,"title":"One speaker treats indirect evidence as a bridge, not a replacement for direct trials"},{"id":"section-4","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: PFS (Assessed by BIRC)"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T07:02:45.780426Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T07:24:41Z","record_hash":"580a17442b170f71f21f6c49711f65c585693b0bc06f65d3073f903cf48702bc","release_hash":"80d8ccd732e265da92d27bf9dd76ff1ef16e2e50fc2df4864d5d457bfb6ebe6e","report_id":"erudio-nct06564324","run_id":"9fa46d3a-2471-4add-928c-c9c3a30df13e","schema_version":"5.0","slug":"trust-iii-nct06564324","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist discussing TRUST-III sees taletrectinib as a possible class leader based on earlier-study comparisons, not trial outcomes. A physician who described helping conduct a matching-adjusted indirect comparison interprets it as favoring taletrectinib over crizotinib, but reports comparable severe treatment-related adverse events. The medical oncologist’s praise for CNS activity and neurologic tolerability does not establish an overall safety advantage. The sources reviewed for this edition contain no results from the trial.","examples":[],"meta_description":"10 sources screened · 12 verified statements (9 from clinicians verified by NPI or staff page) from 4 sources · 3 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T07:24:41Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":10},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","4 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 44 sources about other trials or topics are not included; 1 source that may describe the trial without naming it was not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.","The summarized views come from three commentary sources and cannot establish the prevalence of an opinion among HCPs.","No separate protocol or exact-trial results publication was among the sources reviewed. The registry material describes planned methods, not observed TRUST-III outcomes.","The authors' descriptions of an ongoing comparison and absent direct data are dated to their 2025 posts and interview; they do not establish current trial status.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":2,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":3,"methods":1},"count":4,"evidence_window":{"end":"2025-08-27","start":"2025-04-07"},"retrieval_snapshot":"2026-11-19T06:36:02.085595Z","timeline":[{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W35"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06564324:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06564324:context","quote_policy":"short_quote_link_out"},{"id":"openfda:51ac8e52-3269-4102-8dc8-dba22d82128c:20260921","quote_policy":"short_quote_link_out"},{"id":"openfda:2a51b0de-47d6-455e-a94c-d2c737b04ff7:20261029","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c9896c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1846040592998191445:a0c66bba-90cf-46aa-91cb-e11192bea1e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905288128979718523:0a65b6bc-b9c5-41cb-b958-6e6e83d57b03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1909286953763086404:3390793d-dc18-4743-8fbe-890ce3661459","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933164363088593169:c688a9f3-8e93-4cfe-8423-f7d1e9c97b11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037795266527424686:63946514-1ea4-4293-a5e1-0666eef453ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058123101641249245:615a4814-68b7-4e5b-871d-f4d45a60718a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2081149667446751386:6cb7819d-fd8b-4056-b62d-3f2aea7e7e5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115431501697519943:bbaccd16-a52d-4f88-ae22-ccfb5340255b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qYpYRLC7O9A","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-10-29","start":"2024-10-15"},"retrieval_snapshot":"2026-11-19T06:36:02.085595Z","timeline":[{"count":1,"week":"2024-W42"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W35"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":2,"regulatory":0,"x_thread":3,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Ibtrozi"],"label":"taletrectinib","slug":"taletrectinib"},{"brand_names":["Xalkori"],"label":"crizotinib","slug":"crizotinib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"TRUST-III","aliases":["TRUST-III","A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)"],"brief_title":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non Small Cell Lung Cancer"],"display_condition":"TKI-naïve ROS1-positive locally advanced/metastatic non-small cell lung cancer","display_interventions":[["taletrectinib"]],"enrollment":{"count":194,"type":"ESTIMATED"},"interventions":[{"name":"Taletrectinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Crizotinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06564324","official_title":"A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression-Free-Survival, The time between the beginning of treatment and the occurrence of disease progression or death. Assessed by the blinded Independent Review Committee (BIRC), per RECIST v1.1","measure":"PFS (Assessed by BIRC)","timeFrame":"About 49 months"}],"registered_date":{"date":"2024-08-21","type":"ACTUAL"},"registry_last_updated":"2026-04-13","registry_url":"https://clinicaltrials.gov/study/NCT06564324","short_name":"TRUST-III","short_name_basis":"canonical_name","sponsor":"Nuvation Bio Inc.","start_date":{"date":"2024-11-27","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"AB-106-G318","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}